ValiRx plc (VAL) - Total Assets
Based on the latest financial reports, ValiRx plc (VAL) holds total assets worth £3.10 Million GBP (≈ $4.16 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ValiRx plc book value and equity for net asset value and shareholders' equity analysis.
ValiRx plc - Total Assets Trend (2001–2024)
This chart illustrates how ValiRx plc's total assets have evolved over time, based on quarterly financial data.
ValiRx plc - Asset Composition Analysis
Current Asset Composition (December 2024)
ValiRx plc's total assets of £3.10 Million consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (GBP) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | £0.00 | 36.5% |
| Accounts Receivable | £102.11K | 2.4% |
| Inventory | £69.00K | 1.6% |
| Property, Plant & Equipment | £0.00 | 0.0% |
| Intangible Assets | £530.94K | 12.5% |
| Goodwill | £1.60 Million | 37.6% |
Asset Composition Trend (2001–2024)
This chart illustrates how ValiRx plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of ValiRx plc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ValiRx plc's current assets represent 44.5% of total assets in 2024, a decrease from 94.9% in 2001.
- Cash Position: Cash and equivalents constituted 36.5% of total assets in 2024, down from 45.2% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 37.6% of total assets.
ValiRx plc Competitors by Total Assets
Key competitors of ValiRx plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ValiRx plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.66 | 6.65 | 0.74 |
| Quick Ratio | 8.87 | 6.27 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | £757.13K | £1.02 Million | £-255.33K |
ValiRx plc - Advanced Valuation Insights
This section examines the relationship between ValiRx plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.89 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | 36.2% |
| Total Assets | £4.26 Million |
| Market Capitalization | $3.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values ValiRx plc's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ValiRx plc's assets grew by 36.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ValiRx plc (2001–2024)
The table below shows the annual total assets of ValiRx plc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | £4.26 Million ≈ $5.72 Million |
+36.15% |
| 2023-12-31 | £3.13 Million ≈ $4.20 Million |
-21.27% |
| 2022-12-31 | £3.98 Million ≈ $5.34 Million |
+12.83% |
| 2021-12-31 | £3.52 Million ≈ $4.73 Million |
-28.63% |
| 2020-12-31 | £4.94 Million ≈ $6.63 Million |
+36.98% |
| 2019-12-31 | £3.60 Million ≈ $4.84 Million |
-14.88% |
| 2018-12-31 | £4.23 Million ≈ $5.69 Million |
-14.23% |
| 2017-12-31 | £4.94 Million ≈ $6.63 Million |
-0.50% |
| 2016-12-31 | £4.96 Million ≈ $6.66 Million |
-3.11% |
| 2015-12-31 | £5.12 Million ≈ $6.88 Million |
+41.35% |
| 2014-12-31 | £3.62 Million ≈ $4.87 Million |
-11.77% |
| 2013-12-31 | £4.11 Million ≈ $5.51 Million |
-22.50% |
| 2012-12-31 | £5.30 Million ≈ $7.12 Million |
+16.07% |
| 2011-12-31 | £4.57 Million ≈ $6.13 Million |
+82.60% |
| 2010-12-31 | £2.50 Million ≈ $3.36 Million |
+50.15% |
| 2009-12-31 | £1.67 Million ≈ $2.24 Million |
-6.51% |
| 2008-12-31 | £1.78 Million ≈ $2.39 Million |
+0.79% |
| 2007-12-31 | £1.77 Million ≈ $2.37 Million |
-36.69% |
| 2006-12-31 | £2.79 Million ≈ $3.75 Million |
+1541.76% |
| 2006-03-31 | £170.00K ≈ $228.29K |
+8400.00% |
| 2005-12-31 | £2.00K ≈ $2.69K |
-90.48% |
| 2004-12-31 | £21.00K ≈ $28.20K |
-83.33% |
| 2003-12-31 | £126.00K ≈ $169.21K |
-37.62% |
| 2002-12-31 | £202.00K ≈ $271.27K |
-87.46% |
| 2001-12-31 | £1.61 Million ≈ $2.16 Million |
-- |
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more